Yasserged retweeted
First-line therapy in RCC is a strategic decision that shapes the entire patient journey. Elizabeth Plimack, MD, MS, FASCO, Sundhar Ramalingam, MD, and Yasser Ged, MD, break it down in this 7-episode OncLive Insights series.
Watch now: hubs.li/Q04dqNH90
idneyCancer #Oncology @ERPlimackMD @FoxChaseCancer @MdSundhar @DukeCancer @yasserged @hopkinskimmel
Watch now: hubs.li/Q04dqNH90
idneyCancer #Oncology @ERPlimackMD @FoxChaseCancer @MdSundhar @DukeCancer @yasserged @hopkinskimmel
0
2
1
534
Yasserged retweeted
First-in-human study of [111In] XYIMSR-01 SPECT/CT, a novel carbonic anhydrase IX small molecule in patients with metastatic clear cell #RCC. Presentation by Yasser Ged, MBBS @HopkinsMedicine. #ASCO26 written coverage by @RKSayyid @UAUrology > bit.ly/4dHEtIG @ASCO
0
4
6
491
Yasserged retweeted
Looking forward to a great line-up with GU onc experts from @brady_urology @hopkinskimmel @HopkinsMedicine @sibleyonline featuring @yasserged @CathyHandy @JCensits @akfsurgeon & Mohit Narang. Dinner and great networking opportunity. Thank you @MJHLifeSciences @OncLive !
The future of GU oncology starts with insights from @nirmishsingla, @CathyHandy, @JCensits, Mohit Narang, MD, & Yasser Mohamed Ali Ged, MBBS at the Genitourinary Cancers #OncLiveSOSS on June 10th!
Don't miss out! Register Now: hubs.li/Q03pLwPv0 @hopkinskimmel
0
7
17
1,738
Yasserged retweeted
💫🌟New Review on Testicular Germ Cell Tumors! 🌟💫
@nirmishsingla @AdityaBagrodia
Dr #EzraBaraban @yalepathology @CDFankhauser @yasserged @JAMA_current @OncoAlert
💡 Key Insights:
🧬 Epidemiology & Risk Factors
🔹 Most common solid malignancy in men aged 15-40
🔹 ~10,000 cases annufactors: Cryptorchidism, family history, infertility, cannabis use, Klinefelter syndrome
🩺 Clinical Presentation & Diagnosis
🔹 Painless testicular mass is the most common symptom
🔹 Diagnosis: Scrotal ultrasound + tumor markers (AFP, β-hCG, LDH)
📊 Staging & Treatment
🔹 Stage I (70-75%): Orchiectomy + surveillance or adjuvant therapy 🏥
🔹 Stage II (20%): Lymph node involvement, treated with chemo, RPLND, or RT
🔹 Stage III (10%): Distant metastases → BEP/EP/VIP chemotherapy 💉
🎯 Survival & Long-term Effects
🔹 5-year survival rates: 99% (Stage I), 92% (Stage II), 85% (Stage III)
🔹 Long-term effects: Cardiovascular disease, secondary malignancies, infertility, hypogonadism, psychosocial impact
🧪 Emerging Biomarkers & Future Directions
🔹 miR-371a-3p: High sensitivity (91%) & specificity (94%) for early detection
🔹 Research is ongoing to refine risk stratification & de-escalate treatment
@UCSD_Urology @UCSDCancer @UCSDHealth @DrRanaMcKay @MadamSurgeonMD @cjkane10 @endourologyucsd
@JohnsHopkinsUni1
#OncoUrology #TesticularCancer #UroOncology #OncoTwitter #CancerResearch #MedicalOncology jamanetwork.com/journals/jama/…
@nirmishsingla @AdityaBagrodia
Dr #EzraBaraban @yalepathology @CDFankhauser @yasserged @JAMA_current @OncoAlert
💡 Key Insights:
🧬 Epidemiology & Risk Factors
🔹 Most common solid malignancy in men aged 15-40
🔹 ~10,000 cases annufactors: Cryptorchidism, family history, infertility, cannabis use, Klinefelter syndrome
🩺 Clinical Presentation & Diagnosis
🔹 Painless testicular mass is the most common symptom
🔹 Diagnosis: Scrotal ultrasound + tumor markers (AFP, β-hCG, LDH)
📊 Staging & Treatment
🔹 Stage I (70-75%): Orchiectomy + surveillance or adjuvant therapy 🏥
🔹 Stage II (20%): Lymph node involvement, treated with chemo, RPLND, or RT
🔹 Stage III (10%): Distant metastases → BEP/EP/VIP chemotherapy 💉
🎯 Survival & Long-term Effects
🔹 5-year survival rates: 99% (Stage I), 92% (Stage II), 85% (Stage III)
🔹 Long-term effects: Cardiovascular disease, secondary malignancies, infertility, hypogonadism, psychosocial impact
🧪 Emerging Biomarkers & Future Directions
🔹 miR-371a-3p: High sensitivity (91%) & specificity (94%) for early detection
🔹 Research is ongoing to refine risk stratification & de-escalate treatment
@UCSD_Urology @UCSDCancer @UCSDHealth @DrRanaMcKay @MadamSurgeonMD @cjkane10 @endourologyucsd
@JohnsHopkinsUni1
#OncoUrology #TesticularCancer #UroOncology #OncoTwitter #CancerResearch #MedicalOncology jamanetwork.com/journals/jama/…
1
76
160
16,932
Yasserged retweeted
We report a new role for HIF in the regulation of endogenous retroviruses! It was a big collaborative effort to explore the HIF-mediated transcription, expression, and HLA presentation of ERVs in kidney cancer and leveraging them for immunotherapy
cell.com/cell/fulltext/…
cell.com/cell/fulltext/…
7
51
153
16,339
Yasserged retweeted
Our new study in JITC introduces a dual ERV-based stratification system for predicting immunotherapy efficacy in metastatic ccRCC patients. The model outperforms traditional transcriptomic signatures, offering enhanced precision for ICI treatment outcomes. @jitcancer 🙏Xiaofan Lu
New #JITC article: Stratification system with dual human endogenous retroviruses for predicting immunotherapy efficacy in metastatic clear-cell renal cell carcinoma bit.ly/3Ephlz6 @GabrielMalouf
0
5
14
1,116
Yasserged retweeted
It’s an honor to present my poster at #ASCOGU. Sharing our findings on the impact of Area Deprivation Index on Immunotherapy outcomes in mRCC. Stop by poster D13 to discuss! #CancerResearch #ASCOGU25
0
3
9
797
Yasserged retweeted
Congratulations, Dr. Noah Hahn of @hopkinskimmel and all co-authors on presentation of ADAPT-BLADDER (HCRN-GU16-243) Cohort 4 results at #GU25.
0
8
19
1,453
Yasserged retweeted
Ab#437 @ASCO #GU25 by @VincentWenxinXu👉 bit.ly/3CLElIk👉post-hoc analysis of CheckMate214 #kidneycancer👉⬆️KIM-1 associated w/⬇️OS & KIM-1 reduction correlates w/⬆️ Ipi+Nivo efficacy👇 @OncoAlert @urotoday @Uromigos @KidneyCancer @kidneycan
0
20
38
5,683
Yasserged retweeted
1/7 Pleased to share updated OS results from the #TIVO-3 study (NCT02627963), previously presented at #ESMO24. Our analysis focused on outcomes in patients with #ccRCC who had received prior treatment with a checkpoint inhibitor (CPI) - representing 26% of the trial population.
4
19
37
7,132
Yasserged retweeted
🚨 New AI Tool for Immunotherapy Prediction! 🧠💊
A deep learning model predicts response to ICI in advanced NSCLC using H&E pathology slides! 🏥🔬
✅ Outperforms biomarkers like PD-L1 & TMB
✅ May improve selection for immunotherapy
✅ Hope to see in other tumor types!
A deep learning model predicts response to ICI in advanced NSCLC using H&E pathology slides! 🏥🔬
✅ Outperforms biomarkers like PD-L1 & TMB
✅ May improve selection for immunotherapy
✅ Hope to see in other tumor types!
⚠️Great to keep contributing to this ongoing effort by #MehrdadRakaee and collaborators! @DanaFarber
Histology slides are widely available and can harbor useful information in low-resource settings. This is 1 application in the NSCLC/ICI space.
#lcsm
jamanetwork.com/journals/jamao…
0
1
5
558
Yasserged retweeted
Coming from a patient point of view this is big stuff coming from @DanaFarber @YaleCancer @BraunMDPhD and many others!
1/ JUST IN: an 8 year #kidneycancer journey now published in @Nature: “A personalized neoantigen vaccine generates anti-tumor immunity in high-risk renal cell carcinoma”. A trial of #RCC vaccine, led together with first author @BraunMDPhD @YaleCancer and #PatrickOtt #DerinKeskin r
nature.com/articles/s4158…
@DanaFarber_GU @OncoAlert @DFCI_NeoVax
1
5
10
1,434
Our paper on IO combinations in metastatic translocation RCC is now online. Great collaborative work and addition to treatment outcomes in this rare entity. journals.lww.com/immunotherapy-… @nirmishsingla @montypal @KotechaMD @MattZibelman
2
13
40
2,671
Yasserged retweeted
Special thanks to Drs. Steven Schenkel & Kristin Walter @JAMA_current and @DrNDisis @JAMAOnc for the unique opportunity, & to coauthors @AdityaBagrodia @CDFankhauser @yasserged Ezra Baraban! @HopkinsMedicine @brady_urology @AmerUrological @UroOnc @Uroweb @TestesCancer @TCSociety
Testicular cancer is the most common solid malignancy in young men in the US.
This Review summarizes current evidence regarding risk factors, diagnosis, and treatment of testicular cancer, particularly germ cell tumors, in adults and adolescents.
ja.ma/3CDTEmj
1
5
25
2,939
Yasserged retweeted
Lots to learn from this and other ongoing trials in papillary kidney cancer. S1500 and others show us that it’s possible — please consider this trial for all your patients with this disease.
Don’t forget: @SWOG S2200 is still enrolling patients! Exciting study for a group of us in #kidneycancer who don’t have a lot of #clinicaltrial options: metastatic #papillaryRCC. The amazing @maughanonc is leading #PAPMET2. #nonclearcellRCC #renalcancer
1
7
17
3,435
Yasserged retweeted
Special shout out to co-surgeons @YWLum @wrburnsmd @hopkinssurgery and med onc @yasserged @hopkinskimmel So fortunate to be part of the A-team for our patients @HopkinsMedicine! Great production by @brady_urology @HopkinsMedNews highlighting Chris’s story @TestesCancer @TCSociety
"This is where we were realizing this was a much bigger situation than we thought it was"
Christopher shares his remarkable #testicularcancer journey and how it led him to @HopkinsMedicine where he was treated by a multi-d team led by @nirmishsingla
youtu.be/wI6A-stWZug?si…
0
3
20
2,711
Yasserged retweeted
Can’t miss! The @OncJournal #KCRS24 abstract supplement is out!
🔗 bit.ly/KCRS24Abstract
#KidneyCancer #RCC #AcceleratingCures
@OncoAlert @DrChoueiri @HHammersMD @montypal @DrRanaMcKay @arihakimi @DrYukselUrun
🔗 bit.ly/KCRS24Abstract
#KidneyCancer #RCC #AcceleratingCures
@OncoAlert @DrChoueiri @HHammersMD @montypal @DrRanaMcKay @arihakimi @DrYukselUrun
0
11
20
3,004
Yasserged retweeted
#TiNivo2 results are out —adding PD1 inhibitor nivolumab simply does not help after rechallenge /progression on prior immunotherapy. Time to follow level 1 evidence! @PRNews @TargetedOnc @OncLive @kidneycan @KidneyCancer @Uromigos @OncBrothers —implications beyond renal cancer ? NTACT3
prnewswire.com/news-releases/…
@DanaFarber_GU
prnewswire.com/news-releases/…
@DanaFarber_GU
3
53
119
12,905
Yasserged retweeted
Our paper on liver TACE and immunotherapy in RCC is now online. Great job by Jeffrey Schneider @MarkowskiGUOnc
@drchristosMD americanjir.com/transarterial-… via @https://twitter.com/AmericanJIR
@drchristosMD americanjir.com/transarterial-… via @https://twitter.com/AmericanJIR
0
2
7
360
Our paper on liver TACE and immunotherapy in RCC is now online. Great job by Jeffrey Schneider @MarkowskiGUOnc
@drchristosMD americanjir.com/transarterial-… via @https://twitter.com/AmericanJIR
@drchristosMD americanjir.com/transarterial-… via @https://twitter.com/AmericanJIR
0
2
7
360